Structured Exercise Was Linked to 23% Lower Death Risk in People With Cancer, Review Finds

A new review of 21 randomized trials found that structured exercise was linked to longer survival and more time free of disease in people with cancer. The associations were strongest for aerobic programs, early-stage disease and participants who kept up with their sessions.

Structured exercise may deserve a firmer place in cancer care, according to a systematic review and meta-analysis published online on September 15, 2026, in the British Journal of Sports Medicine. Pooling randomized controlled trials, the researchers found that people with cancer who were given exercise programs as part of their care had better overall survival than people who were not.

The review, by a team with C.-C. Tzang as first author, searched research databases for randomized controlled trials published up to the end of 2025. Eligible trials enrolled adults with confirmed cancer, gave participants structured exercise programs as part of their care, and reported on survival and disease recurrence.

From an initial pool of 123 studies, 21 trials from North America, Europe, Australia and Asia met the eligibility criteria. Together they involved 8,449 participants, 88% of them women. The average age was 54, with a reported range of 47 to 76, and the average monitoring period was 64 months, with a range of 2 to 99 months.

The headline result was clear. People who exercised as part of their care were 23% less likely to die and 17% less likely to have a recurrence before death than people who did not exercise.

What the Structured Exercise Trials Included

The review focused on adults who were assigned structured exercise programs as part of their cancer care, rather than on people who simply reported being active. That distinction shapes how much weight the findings can carry.

Observational studies can show that more active people tend to fare better, but they struggle to separate exercise from other differences between people. Randomized trials assign the program, which makes the comparison between groups cleaner, although the pooled results are still reported as associations.

Breast cancer was the most common diagnosis in the included trials, followed by bowel and pancreatic cancers. The long average monitoring period, more than five years, allowed the analysis to look at recurrence and death rather than only short-term changes in fitness.

Survival, Recurrence and Cancer Deaths: The Numbers

Pooled analysis showed that structured exercise was associated with significant improvements in overall survival. Participants who exercised were 23% less likely to die than those who did not, and 17% less likely to experience a recurrence before death.

Two related measures pointed in the same direction. People in structured exercise groups were 18% less likely to die from any cause and 26% less likely to die from their cancer. The consistency across these outcomes is part of what makes the review notable.

Not every outcome moved, however. According to the BMJ Group summary of the paper, there was no clear evidence that structured exercise prolonged the time before patients’ cancer worsened. The clearest signals involved survival and recurrence, not every marker of disease progression.

Aerobic Programs Stood Out, While Strength Alone Remains Unclear

When the researchers compared types of structured exercise, overall survival estimates favored aerobic exercise alone and programs that combined aerobic exercise with strength training.

No clear association was found for strength training alone. That result should not be read as evidence that lifting is unhelpful for people with cancer. It was based on only one trial involving 129 participants, far too little data to settle the question either way.

The authors offered a physiological rationale for the aerobic finding, writing that aerobic exercise ‘drives systemic cardiovascular conditioning, immune cell mobilisation, and normalisation of tumour perfusion.’ Those are proposed explanations rather than outcomes the pooled trials measured directly.

Different forms of training often carry different health signals. FLM recently covered research in which cardio and strength training were linked to lower diabetes risk, and the new cancer review adds another reason to look closely at which kind of exercise is being studied.

Why Sticking With Structured Exercise Seemed to Matter

An exploratory analysis found that the associations were stronger among participants who completed at least 70% of their structured exercise program. Because the analysis was exploratory, the 70% figure is best treated as a lead for future trials rather than a firm threshold.

Even so, it makes program design a practical question, not just a physiological one. A plan that fits around treatment schedules and daily life may be the plan people are able to complete, and completion appeared to go hand in hand with stronger results.

The review also found that survival and recurrence benefits of structured exercise were strongest in early-stage disease. That does not mean exercise has no role later in the course of illness. It means the available trial evidence on advanced-stage cancer was relatively thin.

How Exercise Might Influence Cancer Outcomes

The researchers outlined several biological pathways that could help explain the associations. Exercise may boost the immune system’s response to cancer and improve blood flow within tumors, potentially helping treatment work better.

It may also lower circulating levels of sex-specific hormones and increase glucose uptake by muscles, leaving less glucose available to fuel cancer cells. In addition, exercise may help cells repair DNA damage, potentially limiting changes that can make tumors more aggressive.

Each of these pathways is plausible, but none was proven by the pooled survival data. The review identifies an association across randomized trials, and the biology describes why researchers think that association could reflect a real effect.

Exercise sets off wide-ranging changes throughout the body. A recent study covered by FLM found that 3 minutes of sprinting changed nearly 25% of blood proteins, a reminder of how many systems a workout can touch.

What the Findings Mean for People Living With Cancer

The authors concluded that clinicians ‘can reasonably recommend structured exercise as part of oncological care, while recognising that important questions remain.’ They added that incorporating the therapeutic potential of exercise into cancer care merits consideration.

For readers, the finding supports a conversation with the care team rather than a do-it-yourself prescription. Here is what the review does and does not suggest:

• It supports asking the oncology team whether a structured exercise program is appropriate.
• It suggests aerobic exercise, alone or combined with strength work, has the most supportive survival evidence so far.
• It hints that completing most of a program may matter, based on an exploratory analysis.
• It does not show that exercise can replace surgery, medication, radiation or any other treatment.
• It does not settle the role of strength training alone or the evidence for advanced-stage disease.

Treatment can change what is safe and realistic from week to week, so program choices are best made with clinicians who know the diagnosis and treatment plan. Structured programs, like those tested in the trials, are designed rather than improvised, which can make them easier to adjust.

FLM has previously reported on a trial in which an exercise-led lifestyle program improved quality of life during prostate cancer hormone therapy. The new review adds a different question, survival, to that picture.

Population research on people without a cancer diagnosis has pointed in a similar direction, including recent data showing that small amounts of vigorous activity were linked to lower mortality. This review, however, applies specifically to adults already living with cancer.